Childhood asthma may increase risk of type 1 diabetes and IBD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Childhood asthma may increase risk of type 1 diabetes and IBD

Latest News

New Trials Favor PE Intervention in Sicker Intermediate-Risk Patients Samantha Pettigrew, MD

Pair Echo With Right Heart Catheterization in PH: Anjali Vaidya, MD Anjali Vaidya, MD, FACC, FASE, FACP

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Experts Examine Biologic Coverage in Asthma and COPD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

CHEST 2026: Day 1 Recap — 5 Headlines to Know

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Recommended News For You

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

High levels of traumatic stress found in caregivers of adult cancer patients

Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.

Black Canadians Face Multiple Barriers to Blood Donation

novel technique for early myelodysplastic syndrome relapse detection in blood cancer patients.

Recommended Articles For You

The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy

Machine Learning in Hematology: Boosting Diagnostic Precision and Speed in Medical Practice

AI Modeling of Tumor Microenvironment States

Evolution of Cancer Care Through Developmental Therapeutics

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.